Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891962 | 0.91 | FFAR1 (0.58) | L3MBTL1FFAR1LMNALTA4HFFAR4 | |
| SCHEMBL2710391 | 0.89 | PPARA (0.61) | L3MBTL1FFAR1LMNALTA4HS1PR1 | |
| SCHEMBL12117110 | 0.86 | L3MBTL1 (0.67) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| SCHEMBL8277617 | 0.83 | L3MBTL1 (0.68) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| SCHEMBL928209 | 0.83 | L3MBTL1 (0.62) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| SCHEMBL11649743 | 0.81 | HRH3 (0.56) | LMNALTA4HTSHRPPARAPPARG | |
| SCHEMBL4842616 | 0.80 | FFAR1 (0.61) | L3MBTL1FFAR1LMNAMMP2FFAR4 | |
| SCHEMBL11949155 | 0.80 | L3MBTL1 (0.76) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| SCHEMBL2468006 | 0.80 | L3MBTL1 (0.69) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| SCHEMBL166364 | 0.80 | ALOX15 (0.63) | FFAR1LTA4HTSHRPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0929567-B1 | SOLID-PHASE PEPTIDE SYNTHESIS | ZEALAND PHARMA AS (DK) | 2005-03-02 | — | — | EP | claimed |
| EP-1018526-B1 | Process for preparing polyurethane foam | GEN ELECTRIC (US) | 2004-10-20 | — | — | EP | claimed |
| US-6664305-B2 | Chromatography material and a process of manufacturing that material | BIA SEPARATIONS D.O.O. (SI) | 2003-12-16 | — | — | US | claimed |
| US-6660781-B1 | Reaction product of tertiary amine and phenoxy acid generates a delayed action catalyst to delay the onset of a reaction between said polyisocyanate, water, and organic polyol | WITCO CORPORATION | 2003-12-09 | — | — | US | claimed |
| US-20030125204-A1 | Chromatography material and a process of manufacturing that material | BIA SEPARATIONS D.O.O. (SI) | 2003-07-03 | — | — | US | claimed |
| EP-1294480-A1 | A CHROMATOGRAPHY MATERIAL AND A PROCESS OF MANUFACTURING THAT MATERIAL | Bia Separations D.O.O. (SI) | 2003-03-26 | — | — | EP | claimed |
| WO-2002000337-A1 | A CHROMATOGRAPHY MATERIAL AND A PROCESS OF MANUFACTURING THAT MATERIAL | BIA SEPARATIONS D.O.O. (SI) | 2002-01-03 | — | — | WO | claimed |
| EP-1018526-A1 | Process for preparing polyurethane foam | CK WITCO CORPORATION (US) | 2000-07-12 | — | — | EP | claimed |
| EP-0929567-A1 | IMPROVED SOLID-PHASE PEPTIDE SYNTHESIS AND AGENT FOR USE IN SUCH SYNTHESIS | Zealand Pharmaceuticals A/S (DK) | 1999-07-21 | — | — | EP | claimed |
| US-5877214-A | Polyaryl-poly(ethylene glycol) supports for solution-phase combinatorial synthesis | MERCK & CO., INC. (US) | 1999-03-02 | — | — | US | claimed |
| US-5858534-A | FOR SOLID PHASE SYNTHESIS; POLYSTYRENE COATED METAL OXIDE PARTICLES DISPERSED IN POLYSTYRENE MATRIX | SOLID PHASE SCIENCES CORP. (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998011125-A1 | IMPROVED SOLID-PHASE PEPTIDE SYNTHESIS AND AGENT FOR USE IN SUCH SYNTHESIS | ZEALAND PHARMACEUTICALS A/S (DK) | 1998-03-19 | — | — | WO | claimed |
| EP-0608779-A1 | Apparatus for peptide synthesis | SHIMADZU CORPORATION (JP) | 1994-08-03 | — | — | EP | claimed |
| US-12492225-B2 | Melanocyte-regulating peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2025-12-09 | — | — | US | disclosed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-5877214-A | Polyaryl-poly(ethylene glycol) supports for solution-phase combinatorial synthesis | MERCK & CO., INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5858534-A | FOR SOLID PHASE SYNTHESIS; POLYSTYRENE COATED METAL OXIDE PARTICLES DISPERSED IN POLYSTYRENE MATRIX | SOLID PHASE SCIENCES CORP. (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998011126-A1 | PEPTIDE PRODRUGS CONTAINING AN ALPHA-HYDROXYACID LINKER | ZEALAND PHARMACEUTICALS A/S (DK) | 1998-03-19 | — | — | WO | disclosed |
| US-5601992-A | DETECTING INTERACTION BETWEEN PEPTIDE AND TARGET BY PLACING TARGET INTO CONTAINER, OVERLAYING WITH SUBSTRATE, APPLYING BEADS TO SUBSTRATE, EACH BEAD HAVING ASSOCIATED THEREWITH COPIES OF A SINGLE PEPTIDE, ALLOWING DIFFUSION, REACTION | BUNSEN RUSH LABORATORIES, INC. (US) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492225-B2 | Melanocyte-regulating peptides | MC1R, MITF, MCHR1 | L3MBTL1 132/4885FFAR1 4602/4885LMNA 4620/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | L3MBTL1 1349/4885FFAR1 490/4885LMNA 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.